A Deep Dive Into the Role of PARP Inhibitors: Equipping Healthcare Professionals With the Necessary Tools for Improving Care in Ovarian Cancer

Read this commentary from Colleen Bohnenkamp PharmD BCOP BCPS and Dane Fritzsche PharmD BCOP on frequently asked questions regarding pharmacists&rsquo use of PARP inhibitors for ovarian cancer.

Share

Program Content

Activities

FAQs: PARPis in OC
Pharmacists’ FAQs on the Use of PARP Inhibitors for Ovarian Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2021

Expires: December 06, 2022

Faculty

cover img faculity

Colleen Bohnenkamp, PharmD, BCOP, BCPS

Oncology Clinical Pharmacist
The University of Kansas Health System
Kansas City, Kansas

cover img faculity

Dane Fritzsche, PharmD, BCOP

Clinical Instructor
Department of Pharmacy
University of Washington
Clinical Oncology Pharmacist
Pharmacy
Seattle Cancer Care Alliance/UW Medicine
Seattle, WA

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie Inc.

GlaxoSmithKline

Partners

CSPE

ProCE Banner

National Association of Specialty Pharmacy

ProCE Banner